vs
波士顿科学（BSX）与希捷科技（STX）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是希捷科技的1.7倍（$5.2B vs $3.1B），波士顿科学净利率更高（25.7% vs 24.0%，领先1.7%），希捷科技同比增速更快（44.1% vs 11.6%），过去两年希捷科技的营收复合增速更高（28.4% vs 12.4%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
希捷科技是全球知名的美国数据存储企业，1978年注册成立时名为舒加特科技，1979年正式开展业务，2010年起注册地变更为爱尔兰都柏林，运营总部设在美国加利福尼亚州弗里蒙特，面向全球市场提供专业的数据存储产品与解决方案。
BSX vs STX — 直观对比
营收规模更大
BSX
是对方的1.7倍
$3.1B
营收增速更快
STX
高出32.5%
11.6%
净利率更高
BSX
高出1.7%
24.0%
两年增速更快
STX
近两年复合增速
12.4%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $3.1B |
| 净利润 | $1.3B | $748.0M |
| 毛利率 | 69.5% | 46.5% |
| 营业利润率 | — | 32.1% |
| 净利率 | 25.7% | 24.0% |
| 营收同比 | 11.6% | 44.1% |
| 净利润同比 | 99.0% | -23.8% |
| 每股收益（稀释后） | $0.90 | $3.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXSTX
| Q3 26 | — | $3.1B | ||
| Q1 26 | $5.2B | $2.8B | ||
| Q4 25 | $5.3B | $2.6B | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $5.1B | $2.4B | ||
| Q1 25 | $4.7B | $2.2B | ||
| Q4 24 | $4.6B | $2.3B | ||
| Q3 24 | $4.2B | $2.2B |
净利润BSXSTX
| Q3 26 | — | $748.0M | ||
| Q1 26 | $1.3B | $593.0M | ||
| Q4 25 | $670.0M | $549.0M | ||
| Q3 25 | $755.0M | — | ||
| Q2 25 | $795.0M | $488.0M | ||
| Q1 25 | $672.0M | $340.0M | ||
| Q4 24 | $563.0M | $336.0M | ||
| Q3 24 | $468.0M | $305.0M |
毛利率BSXSTX
| Q3 26 | — | 46.5% | ||
| Q1 26 | 69.5% | 41.6% | ||
| Q4 25 | 69.6% | 39.4% | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | 37.4% | ||
| Q1 25 | 68.8% | 35.2% | ||
| Q4 24 | 67.8% | 34.9% | ||
| Q3 24 | 68.8% | 32.9% |
营业利润率BSXSTX
| Q3 26 | — | 32.1% | ||
| Q1 26 | — | 29.8% | ||
| Q4 25 | 15.6% | 26.4% | ||
| Q3 25 | 20.7% | — | ||
| Q2 25 | 16.2% | 23.2% | ||
| Q1 25 | 19.8% | 20.0% | ||
| Q4 24 | 14.8% | 21.0% | ||
| Q3 24 | 17.4% | 18.6% |
净利率BSXSTX
| Q3 26 | — | 24.0% | ||
| Q1 26 | 25.7% | 21.0% | ||
| Q4 25 | 12.7% | 20.9% | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 15.7% | 20.0% | ||
| Q1 25 | 14.4% | 15.7% | ||
| Q4 24 | 12.3% | 14.5% | ||
| Q3 24 | 11.1% | 14.1% |
每股收益（稀释后）BSXSTX
| Q3 26 | — | $3.27 | ||
| Q1 26 | $0.90 | $2.60 | ||
| Q4 25 | $0.45 | $2.43 | ||
| Q3 25 | $0.51 | — | ||
| Q2 25 | $0.53 | $2.24 | ||
| Q1 25 | $0.45 | $1.57 | ||
| Q4 24 | $0.38 | $1.55 | ||
| Q3 24 | $0.32 | $1.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.1B |
| 总债务越低越好 | — | $3.9B |
| 股东权益账面价值 | — | — |
| 总资产 | — | $8.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BSXSTX
| Q3 26 | — | $1.1B | ||
| Q1 26 | — | $1.0B | ||
| Q4 25 | $2.0B | $1.1B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $534.0M | $891.0M | ||
| Q1 25 | $725.0M | $814.0M | ||
| Q4 24 | $414.0M | $1.2B | ||
| Q3 24 | $2.5B | $1.2B |
总债务BSXSTX
| Q3 26 | — | $3.9B | ||
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | — | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $9.2B | — |
股东权益BSXSTX
| Q3 26 | — | — | ||
| Q1 26 | — | $459.0M | ||
| Q4 25 | $24.2B | $-63.0M | ||
| Q3 25 | $23.4B | — | ||
| Q2 25 | $22.4B | $-453.0M | ||
| Q1 25 | $22.2B | $-829.0M | ||
| Q4 24 | $21.8B | $-1.1B | ||
| Q3 24 | $20.7B | $-1.3B |
总资产BSXSTX
| Q3 26 | — | $8.9B | ||
| Q1 26 | — | $8.7B | ||
| Q4 25 | $43.7B | $8.4B | ||
| Q3 25 | $42.7B | — | ||
| Q2 25 | $41.6B | $8.0B | ||
| Q1 25 | $40.1B | $7.6B | ||
| Q4 24 | $39.4B | $8.0B | ||
| Q3 24 | $38.1B | $8.0B |
负债/权益比BSXSTX
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $2.4B |
| 自由现金流经营现金流 - 资本支出 | — | $953.0M |
| 自由现金流率自由现金流/营收 | — | 30.6% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.17× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BSXSTX
| Q3 26 | — | $2.4B | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $532.0M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | $508.0M | ||
| Q1 25 | $541.0M | $259.0M | ||
| Q4 24 | $1.5B | $221.0M | ||
| Q3 24 | $1.0B | $95.0M |
自由现金流BSXSTX
| Q3 26 | — | $953.0M | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $427.0M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | $425.0M | ||
| Q1 25 | $354.0M | $216.0M | ||
| Q4 24 | $1.2B | $150.0M | ||
| Q3 24 | $823.0M | $27.0M |
自由现金流率BSXSTX
| Q3 26 | — | 30.6% | ||
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 16.2% | ||
| Q3 25 | 22.9% | — | ||
| Q2 25 | 22.3% | 17.4% | ||
| Q1 25 | 7.6% | 10.0% | ||
| Q4 24 | 25.8% | 6.5% | ||
| Q3 24 | 19.6% | 1.2% |
资本支出强度BSXSTX
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 4.0% | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 3.1% | 3.4% | ||
| Q1 25 | 4.0% | 2.0% | ||
| Q4 24 | 6.1% | 3.1% | ||
| Q3 24 | 4.3% | 3.1% |
现金转化率BSXSTX
| Q3 26 | — | 3.17× | ||
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 0.97× | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.62× | 1.04× | ||
| Q1 25 | 0.81× | 0.76× | ||
| Q4 24 | 2.59× | 0.66× | ||
| Q3 24 | 2.14× | 0.31× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
STX
暂无分部数据
